GLP-1 RA for Stage 1 Type 1 Diabetes

NCT07430332 on ClinicalTrials.gov · last registry update 2026-02-24

A small phase 2 — 15 participants, against a typical 110. Due to report 1 June 2029, alongside 14 other tracked readouts that quarter. Primary outcome, as filed: C-peptide area under the curve. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: NOT_YET_RECRUITING
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Children's Hospital Medical Center, Cincinnati
Sponsor type: Other
Enrollment: 15
Started: 2027-09-01
Primary completion: 2029-06-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

C-peptide area under the curve

Conditions studied

Stage 1 Diabetes Mellitus, Type 1

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.